-- Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment (TME).
-- Inceptor Bio was established to pursue a diversified cell therapy portfolio with 'differentiation that matters' across multiple cell types including CAR-T, CAR-macrophage (CAR-M) and NK / NKT.
-- Inceptor Bio is building Advanced Manufacturing Platform (AMP+), a fit for purpose, capital efficient, and scalable 'mini-mill' at the core of a shared infrastructure strategy to maintain control of critical viral vector and cell therapy operations.
-- Inceptor Bio announced that it had raised $26 million in its seed round.
Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotech, announced today that it is developing multiple next-generation cell and gene therapy platforms to cure difficult-to-treat cancers. Inceptor Bio will create a portfolio of companies focused on specific platform technologies, supported by its Advanced Manufacturing Platform (AMP+) and other shared infrastructure.
Inceptor Bio was established to pursue a diversified portfolio of cell therapy platforms across multiple cell types, including CAR-T, CAR-M, and CAR-NK/NKT, with novel mechanisms that enhance immune cell performance within the tumor microenvironment. The company collaborates with leading scientists at premier academic institutions to license groundbreaking cell and gene technologies.
Inceptor Bio's Advanced Manufacturing Platform (AMP+) is a shared cell and gene therapy manufacturing facility that is central to executing the company's differentiated strategy. AMP+ is a fit-for-purpose, capital efficient, and scalable manufacturing facility that provides expertise and capacity for critical viral vector and cell therapy operations serving all portfolio companies.
Inceptor Bio is led by a management team, Board of Directors, and Scientific Advisory Board that represent an unparalleled breadth of experience in the cell and gene therapy sector, with a track record of execution and successful development of pioneering medicines at industry leaders such as Precision BioSciences, Juno Therapeutics, Brammer Bio, Catalent, and Roche.
Shailesh Maingi, Founder, Chairman and CEO of Inceptor Bio, said, "We started Inceptor Bio with a simple purpose – to provide better options for patients with difficult-to-treat cancers. In solid tumors, where there are limited treatment options, patient outcomes remain poor, and cures are elusive. But there is hope with advances in cell and gene therapy. Our mission is consequently to advance multiple next-generation CAR-T, CAR-M and CAR-NK/NKT platforms in collaboration with leading universities to cure these cancers.
Maingi continued, "We are privileged to have an outstanding team of pioneers in cell and gene therapy executing our vision. Our operations strategy starts with AMP+, our Advanced Manufacturing Platform for viral vector and cell therapy operations, which allows us to maintain internal control of development and manufacturing. We are delighted to partner with leading academic collaborators in our shared mission to end cancer."
The seed round was led by the Kineticos Disruptor Fund. Frank Lis, Kineticos Ventures President and CEO, said, "We are delighted to lead the seed round for Inceptor Bio, which has an exceptional cell and gene therapy team, dedicated manufacturing in AMP+, and a unique collaborative model with top research universities. The products being developed by Inceptor Bio will have a profound impact on the lives of many cancer patients."
